$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos

$abos Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000157688524000098 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$5.018M	$5.193M
YoY Change		3.25%	48.29%
% of Gross Profit
Research & Development		$27.25M	$13.29M
YoY Change		143.73%	23.7%
% of Gross Profit
Depreciation & Amortization		$16.00K	$21.00K
YoY Change		60.0%	75.0%
% of Gross Profit
Operating Expenses		$32.27M	$18.49M
YoY Change		101.17%	29.74%
Operating Profit		-$32.27M
YoY Change		101.17%
Interest Expense		$2.467M	$2.010M
YoY Change		-21.03%	44.4%
% of Operating Profit
Other Income/Expense, Net		$2.500M	-$21.00K
YoY Change		-18.88%	110.0%
Pretax Income		-$29.77M	-$16.50M
YoY Change		129.67%	28.22%
Income Tax
% Of Pretax Income
Net Earnings		-$29.77M	-$16.50M
YoY Change		129.72%	28.22%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.50
Diluted Earnings Per Share		-$0.50	-$0.28
COMMON SHARES
Basic Shares Outstanding	60.08M shares	60.08M shares	57.91M shares
Diluted Shares Outstanding		60.08M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$200.3M	$243.5M
YoY Change	-7.0%	37.11%
Cash & Equivalents	$33.18M	$66.89M
Short-Term Investments	$167.2M	$176.6M
Other Short-Term Assets	$457.0K	$3.093M
YoY Change	152.49%	1205.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$268.0K	$0.00
Total Short-Term Assets	$207.6M	$246.6M
YoY Change	-5.02%	36.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$89.00K	$503.0K
YoY Change	-27.64%	204.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$58.55M	$62.55M
YoY Change	-13.0%	294.98%
Other Assets	$170.0K	$454.0K
YoY Change	-10.05%	200.66%
Total Long-Term Assets	$59.34M	$63.51M
YoY Change	-12.44%	290.64%
TOTAL ASSETS
Total Short-Term Assets	$207.6M	$246.6M
Total Long-Term Assets	$59.34M	$63.51M
Total Assets	$267.0M	$310.1M
YoY Change	-6.77%	57.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.342M	$1.379M
YoY Change	71.95%	-15.91%
Accrued Expenses	$4.926M	$10.62M
YoY Change	55.49%	75.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$756.0K
YoY Change
Total Short-Term Liabilities	$19.91M	$12.97M
YoY Change	226.57%	66.04%
LONG-TERM LIABILITIES
Long-Term Debt	$29.67M	$29.90M
YoY Change
Other Long-Term Liabilities	$185.0K	$284.0K
YoY Change
Total Long-Term Liabilities	$29.86M	$30.18M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.91M	$12.97M
Total Long-Term Liabilities	$29.86M	$30.18M
Total Liabilities	$49.77M	$43.15M
YoY Change	716.22%	452.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$288.0M	-$222.8M
YoY Change	39.6%	30.75%
Common Stock	$6.000K	$6.000K
YoY Change	0.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$217.2M	$267.0M
YoY Change
Total Liabilities & Shareholders Equity	$267.0M	$310.1M
YoY Change	-6.77%	57.75%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$29.77M	-$16.50M
YoY Change	129.72%	28.22%
Depreciation, Depletion And Amortization	$16.00K	$21.00K
YoY Change	60.0%	75.0%
Cash From Operating Activities	-$24.60M	-$8.314M
YoY Change	90.67%	-25.79%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$11.00K
YoY Change	-100.0%	-68.57%
Acquisitions
YoY Change
Other Investing Activities	-$10.13M	-$48.79M
YoY Change	-88.99%	139.34%
Cash From Investing Activities	-$10.13M	-$48.81M
YoY Change	-88.99%	139.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-42.00K	29.13M
YoY Change	-100.03%	596.3%
NET CHANGE
Cash From Operating Activities	-24.60M	-8.314M
Cash From Investing Activities	-10.13M	-48.81M
Cash From Financing Activities	-42.00K	29.13M
Net Change In Cash	-34.77M	-27.99M
YoY Change	-294.57%	2.02%
FREE CASH FLOW
Cash From Operating Activities	-$24.60M	-$8.314M
Capital Expenditures	$0.00	$11.00K
Free Cash Flow	-$24.60M	-$8.325M
YoY Change	90.52%	-25.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address City Or Town EntityAddressCityOrTown	Newton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02465
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	344-4190
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	ABOS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q3	us-gaap	Liabilities Liabilities	49773000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60079778	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60079778	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-287973000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	217202000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	266975000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27247000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	682000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2338000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-29765000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	168874000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1600000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-12957000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	280273000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	343000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	15000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	62553000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	238879000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	522000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	212000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	239189000	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Type DocumentType	10-Q
	dei	Entity File Number EntityFileNumber	001-40551
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-4108129
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1210-1220 Washington Street
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	167159000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7289000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	207632000	usd
CY2024Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	58552000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170000	usd
CY2024Q3	us-gaap	Assets Assets	266975000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2342000	usd
CY2024Q3	abos	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	12517000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4926000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33184000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42652000	usd
	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	296000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	236000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	89000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	129000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	19914000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	185000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	29674000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57910461	shares
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	518000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001576885
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	Acumen Pharmaceuticals, Inc.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60079778	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66886000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	176636000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3093000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	62553000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	381000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	233000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	122000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	221000	usd
CY2023Q4	us-gaap	Assets Assets	310125000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1379000	usd
CY2023Q4	abos	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	4387000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	usd
CY2024Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	756000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	110000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12971000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	284000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	29897000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	43152000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	504651000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	489453000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222798000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	312000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	266973000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11179000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59229000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29025000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5018000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4860000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15191000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13627000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	32265000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	16039000	usd
	us-gaap	Operating Expenses OperatingExpenses	74420000	usd
	us-gaap	Operating Expenses OperatingExpenses	42652000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-32265000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16039000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-74420000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3504000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3124000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11325000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6840000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1027000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3031000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
CY2024Q3	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-10000	usd
CY2023Q3	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	1040000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-89000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-62000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2500000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3082000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9245000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6778000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-12957000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65175000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-35874000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	682000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	137000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	242000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29083000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12820000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64969000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35632000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60079778	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60079778	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54229630	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54229630	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59990844	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59990844	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	243947000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	217202000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	us-gaap	Assets Current AssetsCurrent	246615000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57910461	shares
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310125000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-29765000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	206000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45474953	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45474953	shares
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	122294000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	325000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	137000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	266973000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7938000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-32000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	206000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7292000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65175000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	217202000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	188775000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	122294000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	325000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	242000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4511000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-35874000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	280273000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-65175000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-35874000	usd
	us-gaap	Depreciation Depreciation	49000	usd
	us-gaap	Depreciation Depreciation	42000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7292000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4511000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4599000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1344000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	1040000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	85000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	103000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	97000	usd
	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	0	usd
	abos	Other Noncash Expense Interest OtherNoncashExpenseInterest	823000	usd
	abos	Other Noncash Expense Interest OtherNoncashExpenseInterest	0	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	230000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4196000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	436000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-51000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	38000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	963000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-278000	usd
	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	8130000	usd
	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	-1151000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1413000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-182000	usd
	abos	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability	-23000	usd
	abos	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-80000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-103000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34750000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	155631000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	178857000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	174011000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	55997000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	16000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	7000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18364000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-122864000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7938000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	122294000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	739000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	abos	Payments For Deferred Offering Costs PaymentsForDeferredOfferingCosts	230000	usd
	abos	Payments For Deferred Offering Costs PaymentsForDeferredOfferingCosts	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	32000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	325000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6937000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	122619000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-33699000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34995000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67119000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130101000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33420000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95106000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	2235000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	abos	Proceeds From Sale Of Property Plant And Equipment Noncash Investing And Financing Activities ProceedsFromSaleOfPropertyPlantAndEquipmentNoncashInvestingAndFinancingActivities	0	usd
	abos	Proceeds From Sale Of Property Plant And Equipment Noncash Investing And Financing Activities ProceedsFromSaleOfPropertyPlantAndEquipmentNoncashInvestingAndFinancingActivities	4000	usd
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acumen Pharmaceuticals, Inc. (“Acumen” or the “Company”) was incorporated in 1996 in the state of Delaware. Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what the Company believes to be a key underlying cause of Alzheimer’s disease (“AD”). Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. The Company’s scientific founders pioneered research on soluble amyloid-beta oligomers (“AßOs”), which are globular assemblies of the amyloid-beta (“Aß”) peptide that are distinct from Aß monomers and amyloid plaques. Based on decades of research and supporting evidence, AßOs have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. The Company is currently focused on advancing a targeted immunotherapy drug candidate, sabirnetug, in its Phase 2 ALTITUDE-AD clinical trial following the results of INTERCEPT-AD, its Phase 1 clinical trial of sabirnetug in “early AD” patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease), which were first reported in July 2023. Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (“IgG2”) monoclonal antibody (“mAb”) that was designed to selectively target AßOs, has demonstrated functional and protective effects in in vitro assays, and has previously demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic mouse models for AD. The Company has amended the ALTITUDE-AD clinical trial protocol from a Phase 2/3 study to a Phase 2 standalone study. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the uncertainty of whether its intellectual property will develop into successful commercial products. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $288.0 million and $222.8 million, respectively, and working capital of $187.7 million and $233.6 million, respectively. Management believes that the Company has sufficient cash to continue operating activities for beyond 12 months from issuance of these condensed financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future capital requirements will depend upon many factors, including the timing and extent of spending on research and development and market acceptance of the Company’s products, if approved for commercial sale. The Company expects that it will need to obtain additional financing to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. Until such time, if ever, as the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. There can be no assurance that any such financing will be available on terms acceptable to the Company, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product discovery and development activities or future commercialization efforts. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its INTERCEPT-AD clinical trial in the second quarter of 2023. This trial enrolled 65 patients and 62 participants received at least one dose of study drug. INTERCEPT-AD was a U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial with overlapping single ascending dose and multiple ascending dose cohorts evaluating patients with early AD. In July 2023, the Company announced topline results from INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this study in 62 participants with early AD. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company announced the dosing of the first patient in our Phase 2 ALTITUDE-AD clinical trial in May 2024, and expects to complete enrollment in the first half of 2025.</span></div>
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288000000.0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222800000	usd
CY2024Q3	abos	Working Capital WorkingCapital	187700000	usd
CY2023Q4	abos	Working Capital WorkingCapital	233600000	usd
CY2023Q2	abos	Number Of Patients Enrolled In Trial NumberOfPatientsEnrolledInTrial	65	patient
CY2023Q2	abos	Number Of Participants Enrolled In Trial With One Dose Of Study Drug Received NumberOfParticipantsEnrolledInTrialWithOneDoseOfStudyDrugReceived	62	participant
CY2023Q3	abos	Number Of Participants Enrolled In Trial With One Dose Of Study Drug Received With Primary And Secondary Objectives Met NumberOfParticipantsEnrolledInTrialWithOneDoseOfStudyDrugReceivedWithPrimaryAndSecondaryObjectivesMet	62	participant
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements, as well as the reported amounts of expenses during the reporting periods. These estimates and assumptions are based on the Company’s historical experience, and on various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results may differ from these estimates under different assumptions or conditions. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. The more significant estimates and assumptions by management include, among others: the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of stock options and the valuation of embedded derivatives within the Company’s long-term debt.</span></div>
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	32800000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	66200000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33184000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66886000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	236000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	233000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33420000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67119000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	166819000	usd
CY2024Q3	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	358000	usd
CY2024Q3	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	18000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	167159000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	58374000	usd
CY2024Q3	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	179000	usd
CY2024Q3	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	1000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	58552000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	225193000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	537000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	19000	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	225711000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	176654000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	179000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	197000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	176636000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	62225000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	13351000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	12336000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	13000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	25687000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	19000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	84580000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	158000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	12074000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	54000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	96654000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	212000	usd
	abos	Debt Securities Available For Sale Noncurrent Term DebtSecuritiesAvailableForSaleNoncurrentTerm	P2Y
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	258543000	usd
CY2024Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	1520000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1520000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	305396000	usd
CY2023Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2560000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2560000	usd
CY2024Q3	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	5359000	usd
CY2023Q4	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	1680000	usd
CY2024Q3	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	1011000	usd
CY2023Q4	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	807000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	268000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2024Q3	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	143000	usd
CY2023Q4	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	98000	usd
CY2024Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	51000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	225000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	457000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	283000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7289000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3093000	usd
CY2024Q3	abos	Research And Development Noncurrent ResearchAndDevelopmentNoncurrent	122000	usd
CY2023Q4	abos	Research And Development Noncurrent ResearchAndDevelopmentNoncurrent	221000	usd
CY2024Q3	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	48000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	0	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	221000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2778000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3692000	usd
CY2024Q3	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	1706000	usd
CY2023Q4	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	2186000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	241000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	249000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	201000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	212000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4926000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	usd
CY2024Q3	abos	Common Stock And Preferred Stock Shares Authorized CommonStockAndPreferredStockSharesAuthorized	310000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	abos	Common Stock Number Of Voting Rights CommonStockNumberOfVotingRights	1	votingright
CY2022Q3	abos	Sale Of Stock Commission Rate To Sales Agents SaleOfStockCommissionRateToSalesAgents	0.030
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2338000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1600000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7292000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4511000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7523947	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2961850	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	57871	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	53555	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.10
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10374371	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.88
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4461000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	5664870	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.48
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4186000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13504612	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7728647	shares
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001576885-24-000098-index-headers.html	Edgar Link	pending
0001576885-24-000098-index.html	Edgar Link	pending
0001576885-24-000098.txt	Edgar Link	pending
0001576885-24-000098-xbrl.zip	Edgar Link	pending
abos-20240930.htm	Edgar Link	pending
abos-20240930.xsd	Edgar Link	pending
abos-20240930x10qxexx311.htm	Edgar Link	pending
abos-20240930x10qxexx312.htm	Edgar Link	pending
abos-20240930x10qxexx321.htm	Edgar Link	pending
abos-20240930x10qxexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
abos-20240930_cal.xml	Edgar Link	unprocessable
abos-20240930_def.xml	Edgar Link	unprocessable
abos-20240930_lab.xml	Edgar Link	unprocessable
abos-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abos-20240930_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos

2024 Q4 Form 10-Q Financial Statement

#000157688524000098 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS Acumen Pharmaceuticals, Inc. Stock $abos

2024 Q4 Form 10-Q Financial Statement

#000157688524000098 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS
Acumen Pharmaceuticals, Inc. Stock $abos